Background: Scedosporiosis is associated with a mortality rate of up to 90% in patients suffering from disseminated infections. Recommended first-line treatment is voriconazole, but epidemiological cut-off values and clinical breakpoints have not been determined.
Introduction
Scedosporiosis and fusariosis are the most frequent mould infections, after aspergillosis. 1 In temperate climate zones, scedosporiosis is commonly caused by members of the 'Scedosporium apiospermum species complex' (containing the former species: Pseudallescheria ellipsoidea, Pseudallescheria fusoidea, Pseudallescheria angusta and Pseudallescheria boydii).
2 These fungi cause a broad spectrum of diseases in both immunocompetent and immunocompromised patients. 3 Their special features are a pronounced neurotropism and resistance to most systemic antifungals (amphotericin B, itraconazole, flucytosine and echinocandins). In immunocompetent patients scedosporiosis is predominantly localized, but the majority of immunosuppressed patients (.50%) suffer from disseminated infections (mortality rates: 58%-75%). Particularly high mortality rates (.90%) are seen in patients with CNS involvement; in immunosuppressed patients, Scedosporium disseminates via haematogenous spread, while CNS scedosporiosis is seen in immunocompetent patients, exclusively after near-drowning. 3, 4 Although neither species-specific epidemiological cut-off values (ECVs) nor clinical breakpoints (CBPs) have been established for Scedosporium spp., case reports 3 and currently available treatment guidelines 5 suggest voriconazole (with or without surgery) as first-line treatment for scedosporiosis. Voriconazole reaches high CNS-substance levels. 4 However, a comprehensive evaluation of voriconazole treatment outcome in experimental disseminated scedosporiosis and a correlation with MIC values is lacking. Therefore, the objectives of this study were to determine if in vivo efficacy of voriconazole correlates with MIC values and to suggest a species-specific experimental tentative cut-off value. In addition, we aimed to evaluate the performance of two commercial antifungal susceptibility tests [Etest and disc diffusion test (DDT)] in comparison with the gold standard method (CLSI broth microdilution), to offer alternatives for routine laboratory testing.
Materials and methods

In vitro antifungal susceptibility testing
Twenty-eight clinical isolates and three of environmental origin were used in the in vitro studies (Table 1 ). All isolates were previously identified by sequencing the internal transcribed spacer (ITS) region and the b-tubulin gene. The sequences were compared using blast against two in-house databases and the ISHAM ITS database (http://its.mycologylab.org/). The isolates were subcultured on potato dextrose agar (PDA) for 10 days at 30 C and inocula were prepared as previously described. 6 Voriconazole MIC values were determined using: (i) broth microdilution according to the CLSI M38-A2 document (international gold standard); 7 (ii) disc diffusion using non-supplemented Mueller-Hinton agar and 6 mm diameter paper discs containing 1.0 lg of voriconazole; 8 and (iii) Etest (bioMérieux SA, Spain), according to the manufacturer's instructions. The strains Paecilomyces variotii ATCC MYA-3630 and Aspergillus fumigatus ATCC MYA-3626 were used as quality controls.
All in vitro tests were incubated at 35 C for 72 h. Broth microdilution MICs were determined according to CLSI using an endpoint of complete growth inhibition. 7 For disc diffusion, inhibition zone diameters (IZDs) were measured to the nearest whole millimetre at the point at which there was a prominent reduction in growth (80%). Slight trailing around the edges was ignored. Etest MIC corresponded to the gradient concentration where the inhibition ellipse intersected the plastic strip. Etest MICs were rounded up to the next higher CLSI concentration for comparison. Strains were categorized as susceptible if the MIC was 2 mg/L and resistant if the MIC was 4 mg/L, on the basis of their response to voriconazole considering as endpoint a reduction in fungal burden in brain (see the next section). DDTs were read as follows: susceptible (IZD 17 mm), intermediate (IZD 14-16 mm) and resistant (IZD 13 mm). 9 The results of Etest and the CLSI broth microdilution method were analysed for their reproducibility by providing essential agreement values within +1 and +2 CLSI dilution steps, as previously described. 10 The minimal fungicidal concentration (MFC) was also determined by subculturing 20 lL from each well that showed complete growth inhibition on PDA plates. The MFC was the lowest drug concentration at which approximately 99.9% of the original inoculum was killed. Each isolate and method was tested in triplicate.
Murine model and ethics
Sixteen strains with different susceptibilities to voriconazole (based on CLSI MIC values) were selected for murine studies ( Table 1) . Groups of 16 OF-1 male mice (8 for fungal burden and 8 for survival analysis) (Charles River, Criffa SA, Barcelona, Spain) were immunosuppressed 2 days before the infection and every 5 days with 200 mg/kg cyclophosphamide. On the day of the infection, OF-1 mice were challenged intravenously with 5 % 10 3 -1 % 10 4 conidia (inoculum size was adjusted to the virulence of each strain as tested in a previous study evaluating survival as endpoint; see Table 2 ) and treated with voriconazole at 40 mg/kg/day orally with grapefruit juice by gavage for 7 days. 11 The dose was selected on the basis of other studies evaluating the efficacy of 40 mg/kg voriconazole in OF-1 mice, where trough serum drug levels obtained were around 4.7-8.2 mg/L after 7-13 days of treatment. 12, 13 Animals received grapefruit juice during and 2 days before initiation of treatment. 12 Brain fungal burden was the study endpoint, but survival and kidney fungal burden were also analysed. For comparability, all animals (control and treated groups) were euthanized after the first animal died in the control group (Table 2) . Organs were worked up as previously described 11 for cfu determination/g of tissue. All animals were housed under standard conditions and care procedures were supervised and approved under the procedure number 8249, by the Universitat Rovira i Virgili Animal Welfare and Ethics Committee.
Statistical analysis
The fungal burdens of the control and treated groups were compared using the Mann-Whitney U-test. The mean survival time (MST) was estimated by the Kaplan-Meier method and compared among groups using the log rank test. All statistical analyses were performed with GraphPad Prism 6.0 for Windows. P values ,0.05 were considered statistically significant.
Results
MICs were 0.125-8.0 mg/L for CLSI broth microdilution and 0.094 to .32.0 mg/L for Etest; IZDs ranged from 0 to 40.0 mm. The susceptibility results for each strain are presented in Table 1 . Based on CLSI broth microdilution, 90.3% of the S. apiospermum strains were susceptible, 6.5% were intermediate and 3.2% were resistant; with Etest, 96.8% were susceptible and 3.2% were resistant. Using DDT, 87.1% of strains were susceptible and 12.9% were resistant. The essential levels of agreement between Etest and CLSI broth microdilution results (Etest MICs within +1 and +2 log 2 dilutions of CLSI broth microdilution MICs) were 87.1% and 93.5%, respectively. We found 6.4% of minor errors between Etest and CLSI broth microdilution and 0% of major and very major errors, with a 93.6% categorical agreement between both methods, while agreement between CLSI broth microdilution and DDT was 90.4%. MFCs for all strains exceeded 16.0 mg/L, confirming the fungistatic activity of voriconazole against S. apiospermum.
Voriconazole resulted in a statistically significant reduction in fungal burden in brain, compared with the control, in 13 of the 16 strains tested, which coincided, with only one exception, with those showing MICs 2 mg/L by CLSI broth microdilution testing (Table 2) Voriconazole MICs can predict outcome in disseminated scedosporiosis
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Discussion
Mortality rates among patients suffering from disseminated scedosporiosis remain high depending on the underlying disease (highest in HSCT recipients) and the site of infection (CNS) and can be up to 90%. 3, 14 ECVs and CBPs have not been established for the interpretation of voriconazole MICs, the currently suggested drug of first-line treatment. Due to the rareness of the disease, these will remain difficult to establish. In contrast to Scedosporium, ECVs for amphotericin B and some azoles have been established for most clinically relevant moulds such as Aspergillus spp., Fusarium spp. and some Mucorales. 15, 16 The present study has some limitations that mean that careful interpretation of the results is required. MIC values of voriconazole for S. apiospermum .1 mg/L are rare, as MIC 90 is ,2 mg/L. 17 Therefore, only a limited set of voriconazole-resistant strains was tested. There is an absence of pharmacokinetic data to confirm that voriconazole exposure in the present model is clinically relevant, and the use of grapefruit may increase the efficacy due to the inhibition of voriconazole metabolism by the mucosal cytochrome enzymes, as previously shown by Liu and Sugar. 12 Our results and the results of other murine models of scedosporiosis demonstrated the efficacy of voriconazole against S. apiospermum, Scedosporium boydii and Scedosporium aurantiacum strains with voriconazole MICs between 0.25 and 1 mg/L. 11, 18, 19 Similar to our results, in a guinea pig model, azole did not show efficacy against one S. apiospermum strain with an MIC of 8.0 mg/L. 20 In the clinical setting, the relevance of susceptibility determination is largely unknown. Most S. apiospermum isolates have voriconazole MICs ,2 mg/L. Considering our results, a therapeutic failure for patients infected with S. apiospermum strains with MIC .2 mg/L is likely when there is CNS involvement. However, alternative therapeutics are lacking due to the multiresistance of these fungi. Posaconazole is one alternative that demonstrated efficacy in treating brain abscesses due to S. apiospermum.
21 Surgical debridement should be considered whenever possible. 5 Overall, our results suggest that voriconazole was able to reduce fungal burden in the brain of 92.3% of all mice challenged with S. apiospermum strains with voriconazole CLSI broth microdilution MICs 2 mg/L and in 33.3% of mice challenged with strains with MICs 4 mg/L. When MICs were determined by Etest, voriconazole showed efficacy against 86.7% of strains with an MIC 2 mg/L, while the single strain with a higher MIC failed to respond. Finally, 91.7% of the strains with an IZD .17 mm and 50% of strains with an IZD ,13 mm responded to the voriconazole therapy when fungal burden in brain was used as the endpoint criterion. In addition, statistical differences (P " 0.039) in brain fungal burden were observed between strains with CLSI MICs 2 mg/L and 4 mg/L, suggesting a reduced treatment response for voriconazole and strains with MICs 4 mg/L. However, significant differences were not found when kidney fungal burden and survival were studied (P " 0.189 and P " 0.133, respectively). This might be due to an organ-specific drug level effect, with higher voriconazole concentrations being reached in the kidneys. Survival differences failed to reach statistical significance between mice challenged with strains of either category (2 mg/L or 4 mg/ L), but were significant when compared with the control; this might be due to the high standard deviations observed within the groups.
In conclusion, our results suggest that voriconazole might show efficacy against strains with voriconazole CLSI MICs 2 mg/L. In addition, Etest and CLSI broth microdilution were found to be suitable methods to generate reliable voriconazole MICs for S. apiospermum strains. Martin-Vicente et al.
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